Very encouraging to see Dr Andrew Mckenzie coming on board As Clinical Development Director with 24 years experience at CSL. Both he and Charmaine have a wealth of experience at CSL taking drugs through clinical trials to market. We are extremely lucky to have them both on our team and clearly they know the potential of our product or they wouldn’t be here with us. I believe that we will see a significant rerate in the SP over the next few months as insto’s recognise that we now have the expertise to take 1102 to commercialisation.. and as Waynesworld has suggested maybe sooner than later.. GLTA
Very encouraging to see Dr Andrew Mckenzie coming on board As...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
0.004(6.25%) |
Mkt cap ! $61.30M | |||
| Open | High | Low | Value | Volume |
| 6.6¢ | 7.1¢ | 6.5¢ | $198.2K | 2.885M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14845 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
6.8¢ |
Change
0.004 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 6.6¢ | 7.1¢ | 6.6¢ | 295714 | ||
| Last updated 15.58pm 26/04/2024 ? | |||||
| PER (ASX) Chart |